Cover Image

Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy

Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor immune responses, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency in 2011 at a dose of 3 mg per kilogram of body weight for the treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Eggermont, Alexander (Author) , Chiarion-Sileni, Vanna (Author) , Grob, Jean-Jacques (Author) , Dummer, Reinhard (Author) , Wolchok, Jedd D. (Author) , Schmidt, Henrik (Author) , Hamid, Omid (Author) , Robert, Caroline (Author) , Ascierto, Paolo A. (Author) , Richards, Jon M. (Author) , Lebbé, Céleste (Author) , Ferraresi, Virginia (Author) , Smylie, Michael (Author) , Weber, Jeffrey S. (Author) , Maio, Michele (Author) , Bastholt, Lars (Author) , Mortier, Laurent (Author) , Thomas, Luc (Author) , Tahir, Saad (Author) , Hauschild, Axel (Author) , Hassel, Jessica C. (Author) , Hodi, F. Stephen (Author) , Taitt, Corina (Author) , de Pril, Veerle (Author) , de Schaetzen, Gaetan (Author) , Suciu, Stefan (Author) , Testori, Alessandro (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: The New England journal of medicine
Year: 2018, Volume: 375, Issue: 19, Pages: 1845-1855
ISSN:1533-4406
DOI:10.1056/NEJMoa1611299
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1056/NEJMoa1611299
Verlag, lizenzpflichtig, Volltext: https://www.nejm.org/doi/10.1056/NEJMoa1611299
Get full text
Author Notes:A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J.S. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, J.C. Hassel, F.S. Hodi, C. Taitt, V. de Pril, G. de Schaetzen, S. Suciu, and A. Testori
Description
Summary:Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) to augment antitumor immune responses, was approved by the Food and Drug Administration (FDA) and the European Medicines Agency in 2011 at a dose of 3 mg per kilogram of body weight for the treatment of advanced melanoma.1,2 On the basis of data from a phase 2 trial that indicated the potential for a dose of 10 mg per kilogram to have higher efficacy than the dose of 0.3 mg or 3 mg per kilogram in patients with advanced melanoma, although at a cost of more . . .
Item Description:Published on October 8, 2016, and updated on November 9, 2018
Gesehen am 05.06.2020
Physical Description:Online Resource
ISSN:1533-4406
DOI:10.1056/NEJMoa1611299

Similar Items